SpectrumX starts work on a facility that will produce a pioneering, safe non-alcohol hand sanitiser

0
50

SpectrumX Holdings Ltd said it has broken ground on a new facility in the northwest of England that will produce a pioneering, safe non-alcohol hand sanitiser that offers a new weapon in the fight against the spread of Covid infection.


It has signed a lease in Knutsford, Cheshire, from where it will manufacture Spectricept and a “range of other innovative pharmaceutical and cosmetic products”.


The chemical technology behind Spectricept mimics a weak acid used by the body’s defence system to ward off germs and infections but is completely harmless if ingested and far kinder to the skin than the traditional hand cleansers.


To read more about the company’s pre-IPO funding round, click here


SpectrumX is one of the few UK companies supplying non-alcohol-based sanitisers to the NHS, and it is at the forefront in lobbying government to endorse non-alcohol products, especially in schools.


Member of Parliament for Tatton, Esther McVey (pictured), joined operations director, Ben Hibbert, and general manager, Richard Jones, to walk through the proposed facility.


She said: “I am keen to promote alcohol-free sanitisers in circumstances where there is a risk to health and safety and I will be supporting SpectrumX and other producers in putting the case to the government.”



Local MP Esther McVey inspects plans for the new site


The product is based around a chemical known as hypochlorous acid (HOCl), used by the body’s own defences to destroy viruses and bacteria.


Proceeds from a pre-IPO fundraising round will be used to begin the commercial roll-out of Spectricept, but also to start clinical trials of SPC-069, a respiratory candidate that harnesses the HOCl to combat Covid. It will undergo phase II clinical trials in Austria shortly.


The 240 people taking part in the study will be put on a 10-day course of the treatment, which means the top-line results from the study should be available reasonably quickly after the start of the evaluation, said Damien Hancox, the chief executive of SpectrumX.


“Anecdotally, we have seen excellent improvements in 72 hours,” he adds.


A broad-based antimicrobial, formulations of SpectrumX’s patent-pending chemical technology could be used to treat viral, bacterial, and fungal infections too.


To learn more about the company’s pre-IPO funding round, click here

LEAVE A REPLY

Please enter your comment!
Please enter your name here